Therefore, a potent anti-cancer chemotherapeutic protocol to co-use cisplatin (or other platinum compounds, such as carboplatin and oxaliplatin) with PARP and ATM inhibitors clinically deserves establishing as it may systemically restore the susceptibility to cisplatin in platinum-refractory recurrent cancers. This evidence concerns the gene ATM and cancer.